This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bellio P., Fagnani L., Nazzicone L., Celenza G.: New and simplified method for drug combination studies by checkerboard assay. MethodsX, 8, 101543 (2021)BellioP.FagnaniL.NazziconeL.CelenzaG.: New and simplified method for drug combination studies by checkerboard assay. MethodsX, 8, 101543 (2021)Search in Google Scholar
Brennan-Krohn T., Kirby J.E.: When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing. Clin. Lab. Med. 39, 345–358 (2019a)Brennan-KrohnT.KirbyJ.E.: When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing. Clin. Lab. Med. 39, 345–358 (2019a)Search in Google Scholar
Brennan-Krohn T., Kirby J.E.: Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method. J.Vis. Exp. 146, 10.3791/58636 (2019b)Brennan-KrohnT.KirbyJ.E.: Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method. J.Vis. Exp. 146, 10.3791/58636 (2019b)Search in Google Scholar
Brennan-Krohn T., Truelson K.A., Smith K.P., Kirby J.E.: Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology. J. Antimicrob. Chemother. 72, 2775–2781 (2017)Brennan-KrohnT.TruelsonK.A.SmithK.P.KirbyJ.E.: Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology. J. Antimicrob. Chemother. 72, 2775–2781 (2017)Search in Google Scholar
Doern C.D.: When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J. Clin. Microbiol. 52, 4124–8 (2014)DoernC.D.: When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J. Clin. Microbiol. 52, 4124–8 (2014)Search in Google Scholar
https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Break point_tables/v_14.0_Breakpoint_Tables.pdf EUCAST. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, valid from 2024-01-01. 19.05.2024https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdfEUCAST. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, valid from 2024-01-01. 19.05.2024Search in Google Scholar
https://atlas.ecdc.europa.eu/public/index.aspx. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases, 13.04.2024https://atlas.ecdc.europa.eu/public/index.aspx. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases, 13.04.2024Search in Google Scholar
Fatsis-Kavalopoulos N., Roemhild R., Tang P.-C., Kreuger J., Andersson D.I.: CombiANT: Antibiotic interaction testing made easy, PLOS Biol. 18, e3000856 (2020)Fatsis-KavalopoulosN.RoemhildR.TangP.-C.KreugerJ.AnderssonD.I.: CombiANT: Antibiotic interaction testing made easy, PLOS Biol. 18, e3000856 (2020)Search in Google Scholar
Gaudereto J.J., Neto L.V.P., Leite G.C., Espinoza E.P.S., Martins R.C.R., Prado G.V.B., Rossi F., Guimarães T., Levin A.S., Costa S.F.: Comparison of methods for the detection of in vitro synergy in multidrug-resistant gram-negative bacteria. BMC Microbiol. 20, 97 (2020)GauderetoJ.J.NetoL.V.P.LeiteG.C.EspinozaE.P.S.MartinsR.C.R.PradoG.V.B.RossiF.GuimarãesT.LevinA.S.CostaS.F.: Comparison of methods for the detection of in vitro synergy in multidrug-resistant gram-negative bacteria. BMC Microbiol. 20, 97 (2020)Search in Google Scholar
Garbusińska A., Szliszka E.: Aktywność leków przeciwdrobno-ustrojowych zastosowanych w kombinacjach wobec pałeczek Gram-ujemnych w badaniach in vitro. Post. N. Med., XXX(08), 427–433 (2017)GarbusińskaA.SzliszkaE.: Aktywność leków przeciwdrobno-ustrojowych zastosowanych w kombinacjach wobec pałeczek Gram-ujemnych w badaniach in vitro. Post. N. Med., XXX(08), 427–433 (2017)Search in Google Scholar
Guzek A.: Metodologia oznaczania synergizmu między antybio-tykami z zastosowaniem pasków z gradientem stężeń antybio-tyków w warunkach in vitro. Forum Zakażeń, 14, 19–24 (2023)GuzekA.: Metodologia oznaczania synergizmu między antybio-tykami z zastosowaniem pasków z gradientem stężeń antybio-tyków w warunkach in vitro. Forum Zakażeń, 14, 19–24 (2023)Search in Google Scholar
Karakonstantis S., Ioannou P., Kofteridis D.D.: In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations. Infection, 50, 569–581 (2022)KarakonstantisS.IoannouP.KofteridisD.D.: In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations. Infection, 50, 569–581 (2022)Search in Google Scholar
Laishram S., Pragasam A.K., Bakthavatchalam Y.D., Veerara-ghavan B.: An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies. Indian J. Med. Microbiol. 35, 445–468 (2017)LaishramS.PragasamA.K.BakthavatchalamY.D.Veerara-ghavanB.: An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies. Indian J. Med. Microbiol. 35, 445–468 (2017)Search in Google Scholar
Marie M.A.M., Krishnappa L.G., Alzahrani A.J., Mubaraki M.A., Alyousef A.A.: A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii. Bosn. J. Basic Med. Sci. 15, 24–29 (2015)MarieM.A.M.KrishnappaL.G.AlzahraniA.J.MubarakiM.A.AlyousefA.A.: A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii. Bosn. J. Basic Med. Sci. 15, 24–29 (2015)Search in Google Scholar
Nasomsong W., Nulsopapon P., Changpradub D., Pungcharoen-kijkul S., Hanyanunt P., Chatreewattanakul T., Santimaleeworagun W.: Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbape-nem-Resistant Pseudomonas aeruginosa. Antibiotics (Basel), 11, 517 (2022)NasomsongW.NulsopaponP.ChangpradubD.Pungcharoen-kijkulS.HanyanuntP.ChatreewattanakulT.SantimaleeworagunW.: Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbape-nem-Resistant Pseudomonas aeruginosa. Antibiotics (Basel), 11, 517 (2022)Search in Google Scholar
Okoliegbe I.N., Hijazi K., Cooper K., Ironside C., Gould I.M.: Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics (Basel), 10, 967 (2021)OkoliegbeI.N.HijaziK.CooperK.IronsideC.GouldI.M.: Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics (Basel), 10, 967 (2021)Search in Google Scholar
Papoutsaki V., Galani I., Papadimitriou E., Karantani I., Karaiskos I., Giamarellou H.: Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates. J. Global Antimicrob. Resist. 20, 98–104 (2020)PapoutsakiV.GalaniI.PapadimitriouE.KarantaniI.KaraiskosI.GiamarellouH.: Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates. J. Global Antimicrob. Resist. 20, 98–104 (2020)Search in Google Scholar
https://pharmaceutical-journal.com/article/news/only-12-new-antibiotics-entered-the-market-in-five-years-who-warns-in-review Sayburn A.: Only 12 new antibiotics entered the market in five years, WHO warns in review. The Pharmaceutical Journal, 310 (2023), 04.12.2024https://pharmaceutical-journal.com/article/news/only-12-new-antibiotics-entered-the-market-in-five-years-who-warns-in-reviewSayburnA.: Only 12 new antibiotics entered the market in five years, WHO warns in review. The Pharmaceutical Journal, 310 (2023), 04.12.2024Search in Google Scholar
Sreenivasan P., Sharma B., Kaur S., Rana S., Biswal M., Ray P., Angrup A.: In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era. J. Antibiot. (Tokyo), 75, 454–462 (2022)SreenivasanP.SharmaB.KaurS.RanaS.BiswalM.RayP.AngrupA.: In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era. J. Antibiot. (Tokyo), 75, 454–462 (2022)Search in Google Scholar
Tang P.-C., Sánchez-Hevia D.L., Westhoff S., Fatsis-Kavalopoulos N., Andersson D.I.: Within-species variability of antibiotic interactions in Gram-negative bacteria. mBio, 15, e0019624 (2024)TangP.-C.Sánchez-HeviaD.L.WesthoffS.Fatsis-KavalopoulosN.AnderssonD.I.: Within-species variability of antibiotic interactions in Gram-negative bacteria. mBio, 15, e0019624 (2024)Search in Google Scholar
https://iris.who.int/bitstream/handle/10665/354545/9789240047655-eng.pdf?sequence=1. WHO. World Health Organization: 2021 Antibacterial agents in clinical and preclinical development: an overview and analysis, 13.04.2024https://iris.who.int/bitstream/handle/10665/354545/9789240047655-eng.pdf?sequence=1. WHO. World Health Organization: 2021 Antibacterial agents in clinical and preclinical development: an overview and analysis, 13.04.2024Search in Google Scholar
https://antybiotyki.edu.pl/wp-content/uploads/Biuletyn/Biuletyn-Informacyjny-2_2022.pdf Żabicka D., Grzegorczyk M.: Oporność na antybiotyki w Polsce i Europie w 2021 roku-dane sieci EARS-Net. Oporność na antybiotyki. Biuletyn informacyjny, 2 (2022), 19.05.2024https://antybiotyki.edu.pl/wp-content/uploads/Biuletyn/Biuletyn-Informacyjny-2_2022.pdfŻabickaD.GrzegorczykM.: Oporność na antybiotyki w Polsce i Europie w 2021 roku-dane sieci EARS-Net. Oporność na antybiotyki. Biuletyn informacyjny, 2 (2022), 19.05.2024Search in Google Scholar
Perfil de Orcid